$CDLX

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

Original reporting
Published Aug 5, 2026, 10:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CDLX
Bearish
medium confidence
Mentioned
$CDLX
Relevance
8/10
alphai data visualization · based on local3news.com
Decision brief

The 30-second read

$CDLXBearishMed
01

Why it matters

Traders can update models and expectations using the disclosed Q2 results and the stated Q3 revenue range for near-term sentiment and positioning.

02

Market read

Company-specific earnings and guidance provide a fresh basis for adjusting near-term expectations for CDLX.

03

What to watch

The article does not include margin, cash flow, or segment detail, so traders may be over-weighting the headline loss without assessing underlying operating trends.

Relevance 8/10Novelty 7/10Timing: reported Q2 results and Q3 revenue guidance on Wednesday

Background

AP earnings snapshot for Cardlytics, including quarterly loss, revenue, and next-quarter revenue guidance.

Company-level read

Ticker impact

$CDLXBearishMedium confidence
Context

Cardlytics reported Q2 loss of $2.58 per share and revenue of $36.9 million, plus Q3 revenue guidance of $34M to $39M.

Expected impact

Likely downside bias on any pre-market reaction if investors focus on losses and the breadth of the revenue outlook.

Evidence & confidence

The article discloses a quarterly loss and provides explicit next-quarter revenue guidance, which typically moves small-cap ad-tech/marketing analytics names on expectations.

Market effects

Adds datapoint on demand and monetization trajectory for customer engagement/marketing analytics providers.

Limited, as the disclosure is company-specific.

Low, no cross-border or macro linkage described.

Counterpoint

Investors may focus less on GAAP loss and more on revenue trajectory versus prior expectations, using the guidance range as a signal of stabilization.

Key entities

  • Cardlytics, Inc.

    Reported Q2 loss and revenue, and provided Q3 revenue guidance range.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.

$AVGOMedAI 9/10

Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs

Broadcom (AVGO) raised its AI chip revenue forecast to $115B for FY2027, up from $100B, and expects $230B in FY2028. This reflects Big Tech's demand for custom chips and networking components, reducing reliance on Nvidia (NVDA). KeyBanc reiterated an Overweight rating and $575 price target for AVGO. AVGO's Q3 revenue rose 86% YoY to $29.6B, but Q4 guidance was slightly below expectations. Hedge funds hold positions in both AVGO and NVDA, with Fisher Asset Management among the top holders.